Business Wire

Hasbro Introduces Ms. Monopoly – First Game in the Franchise that Celebrates Women Trailblazers

10.9.2019 16:00:00 EEST | Business Wire | Press release

Share

Today, Hasbro, Inc. is introducing the first-ever game in the Monopoly franchise that celebrates women trailblazers with Ms. Monopoly. The Ms. Monopoly game marks the first time in the franchise’s history where a new character will grace the cover – and while Mr. Monopoly is a real-estate mogul, Ms. Monopoly is an advocate whose mission is to invest in female entrepreneurs.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190910005160/en/

Ms. Monopoly was created to inspire everyone, young and old as it spotlights women who have challenged the status quo. To celebrate, in lieu of Monopoly winnings, Hasbro surprised young female inventors and entrepreneurs with the recognition they deserve –approximately $20,580 in REAL money to fuel their inventive spirit and further their projects – which just so happens to be the same amount of Monopoly money featured in the game. You can see all of their reactions to the surprise here. All of the young inventors come from very different backgrounds, but with a common goal to help others using their inventions:

  • Sophia Wang, a 16-year-old from Connecticut invented a device that can detect sinkholes before they occur, and after two years of work, her prototype is now 93% accurate. She is hoping to get it patented and in the hands of communities in Florida that are vulnerable to sinkholes.
  • Gitanjali Rao, a 13-year-old from Denver came up with an invention that helps detect lead in drinking water so that individuals can do the test themselves and get results sooner. Her goal is to create an inexpensive, easy to use, portable device so that people all around the world can use it.
  • Ava Canney, a 16-year-old from Ireland, invented a spectrometer that measures the amount of dye in candy and soda. After studying the harmful effects of additives in our food, Ava set out to help people make educated decisions about the toxins they put into their bodies.

“Through the introduction of Ms. Monopoly and the money these young women have received to invest in their future projects, we want to recognize and celebrate the many contributions women have made to our society and continue to make on a daily basis,” said Jen Boswinkel, Senior Director, Global Brand Strategy and Marketing, Hasbro.

Hitting shelves in mid-September, Ms. Monopoly gives new meaning to the franchise, as properties are replaced by groundbreaking inventions and innovations made possible by women throughout history and instead of building houses, you build business headquarters. From inventions like WiFi to chocolate chip cookies, solar heating and modern shapewear, Ms. Monopoly celebrates everything from scientific advancements to everyday accessories – all created by women.

Ms. Monopoly is also the first-ever game where women make more than men – a fun spin in the game that creates a world where women have an advantage often enjoyed by men. However, if men play their cards right, they can make more money too.

Ms. Monopoly is available for pre-order now at Walmart and will be available at most major retailers nationwide and in select countries globally starting September 2019 for a suggested retail price of $19.99.

About Hasbro
Hasbro (NASDAQ: HAS) is a global play and entertainment company committed to Creating the World's Best Play Experiences. From toys and games to television, movies, digital gaming and consumer products, Hasbro offers a variety of ways for audiences to experience its iconic brands, including NERF, MY LITTLE PONY, TRANSFORMERS, PLAY-DOH, MONOPOLY, BABY ALIVE, MAGIC: THE GATHERING and POWER RANGERS, as well as premier partner brands. Through its entertainment labels, Allspark Pictures and Allspark Animation, the Company is building its brands globally through great storytelling and content on all screens. Hasbro is committed to making the world a better place for children and their families through corporate social responsibility and philanthropy. Hasbro ranked No. 13 on the 2019 100 Best Corporate Citizens list by CR Magazine, and has been named one of the World’s Most Ethical Companies® by Ethisphere Institute for the past eight years. Learn more at www.hasbro.com, and follow us on Twitter (@Hasbro) and Instagram (@Hasbro).

HAS-B

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Kristina Timmins
Hasbro, Inc.
Tel: 401-727-5973
Kristina.Timmins@hasbro.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 11:11:00 EEST | Press release

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize

Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 09:00:00 EEST | Press release

Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521069859/en/ Boomi Named One of The Sunday Times Best Places to Work 2026 Boomi's results speak to a workplace culture that goes well beyond industry norms. The company achieved an average employee happiness score of 86%, rated Excellent, with consistent scores across all six dimensions of WorkL's framework. Most strikingly, Boomi's flight risk, the proportion of employees who may be considering leaving, stood at just 3%, against a technology se

LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 08:09:00 EEST | Press release

LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through centers in Romania and Portugal. This would create a more diversified portfolio for LTM – expanding its scale in Europe and Australia, enhancing its position in regulated and high-growth verticals through marquee customer relationships. The deal would augment LTM’s global AI-centric capabilities with local domain and near-shore expertise crucial for delivering digital an

Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 08:00:00 EEST | Press release

Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye